<DOC>
	<DOCNO>NCT01228071</DOCNO>
	<brief_summary>This multicenter , open-label , single arm trial evaluate time eugonadal testosterone range initial testosterone gel 2 % application , time steady state initiation testosterone gel 2 % , dry time application testosterone gel 2 % .</brief_summary>
	<brief_title>Time Eugonadal Range , Time Steady State Drying Time</brief_title>
	<detailed_description>Assessment Time Eugonadal Testosterone Range After Initial Fortesta ( Testosterone ) Gel 2 % Application , Time Steady State After Initiation Fortesta , And Gel Drying Time After Fortesta Application</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Men age 18 65 year . 2 . Have diagnosis primary secondary hypogonadism : Single morning serum total testosterone concentration &lt; 250 ng/dL Two ( 2 ) consecutive morning serum total testosterone concentration &lt; 300 ng/dL ( determine least 1 week apart 3 week screen period ) Total serum testosterone sample must occur 7 AM 11 AM screen 3 . Have body mass index ( BMI ) ≥22 kg/m2 ≤35 kg/m2 . 4 . Have hematocrit level ≤50 % screen 5 . Use reliable contraception subject sexual partner childbearing potential ( woman childbearing potential define postmenopausal , ie , amenorrhea ≥1 year permanently sterile ) . Reliable method contraception : Barrier type device ( eg , condom , female condom , diaphragm , contraceptive sponge ) combination spermicide . Intrauterine device . Oral , injectable , transdermal implantable hormonal contraceptive . 6 . Is able understand give write informed consent 1 . Severe concomitant illness , opinion Investigator , may put subject risk participate trial may influence result trial affect subject ' ability take part trial . 2 . Acute chronic renal impairment [ ( Cr ≥ 1.5x ULN ( upper limit normal ) ] . 3 . Acute chronic hepatic impairment exclude . 4 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 2.5 × ULN ( upper limit normal ) . 5 . Clinically significant , abnormal , baseline laboratory result ( ) , opinion Investigator affect ( ) subject 's suitability trial . 6 . History , exist , clinically significant cardiac disease ( New York Heart Association [ NYHA ] Class III IV ) . 7 . Clinically significant electrocardiogram ( ECG ) abnormalities QTcB QTcF ≥450 msec ; QTc ≥480 msec subject bundle branch block . 8 . Prostate specific antigen ( PSA ) level &gt; 4 ng/mL . 9 . An abnormality digital rectal examination deem suspicious worrisome cancer , nodule asymmetric induration . 10 . Severe symptomatic benign prostatic hyperplasia International Prostate Symptom Score ( IPSS ) &gt; 19 ( screen ) . 11 . Sleep apnea untreated , subject sleep apnea treat ( include cPAP treatment ) opinion investigator clinically unstable 3 month prior screen . 12 . Current eczema , psoriasis , sunburn , clinically significant skin condition application site . 13 . Current abrasion site application . 14 . Malignancy ( suspected malignancy ) type except basal cell carcinoma . Subjects history malignancy must disease free status ≥5 year prior start study treatment . Subjects prostate breast cancer permit participate study . 15 . Known sensitive and/or adverse skin reaction testosterone hormone replacement therapy topical product contain alcohol . 16 . Actively potentially try start family require fertility treatment spouse/partner pregnant . 17 . Participated experimental drug device study within 30 day prior start study treatment . 18 . History alcohol substance abuse within last year . 19 . Taking opioids reason within 3 day screen 20 . Receiving follow medication : Androgen treatment . Androgen antagonist . Application lotion , ointment , steroid application site . 5alphareductase inhibitor ( eg , finasteride , dutasteride ) . 21 . Any subject receive testosterone hormone replacement treatment must abide indicated washout period prior screen total serum testosterone measurement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>testosterone deficiency</keyword>
	<keyword>hypogonadism</keyword>
</DOC>